“Our commitment to therapeutic progress to serve patient needs remains inextricably linked to our commitment to our teams, our stakeholders and the environment.”
President of Servier
2022-2023 Integrated Annual Report
2022-2023 INTEGRATED ANNUAL REPORT
Committed to therapeutic progress to serve patient needs
In a constantly changing world, Servier is adapting and flourishing. Our Integrated Annual Report 2022-2023 showcases this evolution, demonstrating how our company is responding in concrete ways to contemporary societal challenges.
FOREWORD
FOCUS
A new era with new expectations
The world is changing, and so are the mindsets.
There is a growing interest from patients in digital solutions, aspirations for more equitable access to healthcare, and new priorities and desires from employees. Servier is transforming itself to better meet society’s expectations.
FOCUS
Time to accelerate
The post-Covid economic recovery has disrupted conventional practices across the board. The pharmaceutical industry as a whole is undergoing a period of transformation and acceleration.
Companies are striving to maintain competitiveness while sharing their expertise, streamline costs while ensuring continued access to medicines, and incorporate AI while prioritizing the human element in research.
FOCUS
Toward more sustainable growth
We no longer live in a world where economics is pitted against ecology and social responsibility is played off against financial results. Businesses are brimming with creative ways to marry growth and sustainability.
All about Servier
High-performing R&D to serve patient needs
Our ambition is clear: to strengthen our leadership position in select therapeutic areas, especially cancers and rare diseases. To achieve this, our teams are focusing their research efforts, leveraging open innovation and AI.
Our ambition for 2030
Our 2030 strategy fulfils our vocation and takes account of the health challenges facing society today and into the future. We are driven to achieve our ambition as cancer is ever-more prevalent and cardiometabolic diseases still represent a major cause of death around the world.
Making a meaningful social impact for patients and a sustainable world
The notion of corporate social responsibility (CSR) permeates every area of our corporate strategy. It is at the heart of our Servier 2030 ambition.
2022/2023 Dashboard
5.3
€5.3 bn consolidated sales revenue at September 30, 2023
>20%
Share of revenue from brand-name medicines invested in R&D each year
21 900
Employee headcount at September 30, 2023
4.32/5
Overall engagement score among Servier Group employees in 2023
-11 %
Reduction in scope 1 and 2 greenhouse gas emissions compared with previous year